Basics |
Geron Corporation
Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.
|
IPO Date: |
July 31, 1996 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$859.83M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.11 | 2.88%
|
Avg Daily Range (30 D): |
$0.06 | 3.83%
|
Avg Daily Range (90 D): |
$0.07 | 3.12%
|
Institutional Daily Volume |
Avg Daily Volume: |
2.69M |
Avg Daily Volume (30 D): |
11.77M |
Avg Daily Volume (90 D): |
12.91M |
Trade Size |
Avg Trade Size (Sh.): |
342 |
Avg Trade Size (Sh.) (30 D): |
584 |
Avg Trade Size (Sh.) (90 D): |
532 |
Institutional Trades |
Total Inst.Trades: |
2,549 |
Avg Inst. Trade: |
$1.89M |
Avg Inst. Trade (30 D): |
$1.55M |
Avg Inst. Trade (90 D): |
$2.16M |
Avg Inst. Trade Volume: |
.6M |
Avg Inst. Trades (Per Day): |
2 |
Market Closing Trades |
Avg Closing Trade: |
$2.42M |
Avg Closing Trade (30 D): |
$1.65M |
Avg Closing Trade (90 D): |
$2.48M |
Avg Closing Volume: |
805.29K |
|
|
|
|
News |
Apr 29, 2025 @ 2:00 PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investo...
Source: N/A
|
Apr 29, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Reminds Investors That...
Source: N/A
|
Apr 28, 2025 @ 10:50 PM
Geron Corporation Investors: Please contact the Po...
Source: N/A
|
Apr 27, 2025 @ 8:14 PM
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Canopy ...
Source: N/A
|
Apr 24, 2025 @ 5:49 PM
ROSEN, A LEADING NATIONAL FIRM, Encourages Geron C...
Source: N/A
|
Financials |
|
TTM |
Q4 2024 |
FY 2024 |
Basic EPS
|
$-.27
|
$-.04
|
$-.27
|
Diluted EPS
|
$-.27
|
$-.04
|
$-.27
|
Revenue
|
$ 76.99M
|
$ 47.54M
|
$ 76.99M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -174.57M
|
$ -25.35M
|
$ -174.57M
|
Operating Income / Loss
|
$ -173.73M
|
$ -20.05M
|
$ -173.73M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ 9.75M
|
$ 18.71M
|
$ 9.75M
|
PE Ratio
|
|
|
|
|